Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway

Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway

Bibliographic Details
Main Author:	Frontiers Editorial Office
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-05-01
Series:	Frontiers in Oncology
Subjects:	KRAS mutation G12C inhibitor 9 castration-resistant prostate cancer drug resistance metastasis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.707608/full

Similar Items

Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway
by: Jiayu Liu, et al.
Published: (2020-02-01)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
by: Minyong Kang, et al.
Published: (2015-12-01)

Androgen deprivation therapy (castration therapy) and pedophilia: What’s new
by: Mauro Silvani, et al.
Published: (2015-09-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
by: Osamu Ogawa, et al.
Published: (2013-07-01)

Risk or Protective Factors of Prostate Cancer Progressing to Castration Resistant Prostate Cancer After Androgen Deprivation Therapy
by: CHEN Chiwei, et al.
Published: (2020-07-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01)

How do we define “castration” in men on androgen deprivation therapy?
by: Sarin Itty, et al.
Published: (2020-01-01)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
by: Yuki Kita, et al.
Published: (2018-09-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
by: Darren M.C. Poon, et al.
Published: (2015-06-01)

The AhR Ligand, TCDD, Regulates Androgen Receptor Activity Differently in Androgen-Sensitive versus Castration-Resistant Human Prostate Cancer Cells
by: Maryam Ghotbaddini, et al.
Published: (2015-07-01)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01)

Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics
by: Shiv Verma, et al.
Published: (2020-12-01)

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
by: Nicoletta Ferrari, et al.
Published: (2017-12-01)

Preclinical Development of Combination Simvastatin and Metformin Chemotherapy for Metastatic Castration-Resistant Prostate Cancer
by: Babcook, Melissa A.
Published: (2015)

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
by: Caffo O, et al.
Published: (2016-12-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
by: Masaki Shiota, et al.
Published: (2018-12-01)

To Die or to Survive, a Fatal Question for the Destiny of Prostate Cancer Cells after Androgen Deprivation Therapy
by: Paul S. Rennie, et al.
Published: (2011-03-01)

Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man
by: Denise Chronscinski, et al.
Published: (2015-09-01)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
by: Daisuke Obinata, et al.
Published: (2020-10-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
by: Yasuomi Shimizu, et al.
Published: (2018-11-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models
by: Jinny Sun, et al.
Published: (2021-02-01)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
by: Paul S. Rennie, et al.
Published: (2013-06-01)

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01)

A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer
by: Song Liu, et al.
Published: (2017-08-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Replacing prednisolone with dexamethasone to overcome the resistance to abiraterone in castration-resistant prostate cancer: a clinical case
by: A. A. Meshcheryakov, et al.
Published: (2020-07-01)

Safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: a phase II, multicenter, single-arm, open-label study
by: B. Ya. Alekseev, et al.
Published: (2018-04-01)

Darolutamide For Castration-Resistant Prostate Cancer
by: Bastos DA, et al.
Published: (2019-10-01)

Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients
by: Mark A. Underwood, et al.
Published: (2013-08-01)

Clinical relevance of androgen receptor alterations in prostate cancer
by: Emma Jernberg, et al.
Published: (2017-10-01)

A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
by: Peng Gu, et al.
Published: (2019-06-01)

Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer
by: Rafael A. Kaliks, et al.
Published: (2010-06-01)

Retreatment with cabazitaxel in a long-surviving patient with castration-resistant prostate cancer and visceral metastasis
by: Raquel Luque Caro, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_62rnbkh6radf6oj8oistmn18c1